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Abstract: OBJECTIVE To report the clinical features and treatment outcomes of patients with peripap-
illary choroidal neovascular membrane (CNVM) secondary to idiopathic intracranial hypertension (IIH).
METHODS Retrospective, multicenter chart review of patients diagnosed with peripapillary CNVM in
the course of the treatment and follow-up of IIH. RESULTS Records were reviewed from 7 different
institutions between 2006 and 2016. Ten patients (13 eyes) with a diagnosis of IIH and at least 3 months
of follow-up developed CNVM. Three of the total 10 patients developed bilateral CNVM. The mean time
from the diagnosis of IIH to CNVM diagnosis was 41 months. Mean follow-up period was 8 months after
diagnosis of CNVM. All patients were treated with acetazolamide for IIH. Seven eyes were observed, and
6 eyes were given anti-vascular endothelial growth factor (anti-VEGF) injections, including bevacizumab,
ranibizumab, and aflibercept. All CNVMs regressed with subretinal fibrosis, and visual acuity improved
in most patients. Papilledema resolved in only 1 eye, while the other 12 eyes had persistent papilledema
at last follow-up. CONCLUSIONS Peripapillary CNVM, a rare complication of IIH, often resolves spon-
taneously with treatment of IIH. In vision-threatening and/or persistent cases, intravitreal anti-VEGF
treatment may be a safe and effective therapeutic option.
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Objective: To report the clinical features and treatment
outcomes of patients with peripapillary choroidal neovas-
cular membrane (CNVM) secondary to idiopathic intracranial
hypertension (IIH).
Methods: Retrospective, multicenter chart review of pa-
tients diagnosed with peripapillary CNVM in the course of
the treatment and follow-up of IIH.
Results: Records were reviewed from 7 different institutions
between 2006 and 2016. Ten patients (13 eyes) with
a diagnosis of IIH and at least 3 months of follow-up
developed CNVM. Three of the total 10 patients developed
bilateral CNVM. The mean time from the diagnosis of IIH to
CNVM diagnosis was 41 months. Mean follow-up period
was 8 months after diagnosis of CNVM. All patients were
treated with acetazolamide for IIH. Seven eyes were
observed, and 6 eyes were given anti–vascular endothelial
growth factor (anti-VEGF) injections, including bevacizumab,
ranibizumab, and aflibercept. All CNVMs regressed with
subretinal fibrosis, and visual acuity improved in most pa-
tients. Papilledema resolved in only 1 eye, while the other
12 eyes had persistent papilledema at last follow-up.
Conclusions: Peripapillary CNVM, a rare complication of IIH,
often resolves spontaneously with treatment of IIH. In vision-
threatening and/or persistent cases, intravitreal anti-VEGF
treatment may be a safe and effective therapeutic option.
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P
eripapillary choroidal neovascular membrane (CNVM)
is an infrequent cause of vision loss in patients with
idiopathic intracranial hypertension (IIH) (1–3). The prev-
alence of peripapillary CNVM in IIH has previously been
reported as 0.53% (4). There are few reports on the man-
agement of IIH-associated peripapillary CNVM. The diag-
nosis of CNVM is made clinically based on
the identification of a deep peripapillary hemorrhage and
a grayish‐white opacity merged within the area of optic disc
edema. This grayish‐white opacity indicates the presence of
a membrane, which becomes increasingly more apparent on
ophthalmoscopy as intracranial pressure is reduced and pap-
illedema resolves. Diagnosis is assisted by subretinal fluid
demonstrated on optical coherence tomography (OCT).
Likewise, fluorescein angiography (FA) demonstrates hyper-
fluorescence secondary to CNVM leakage, along with an
area of hypofluorescence as subretinal hemorrhage blocks
choroidal transmission.
In most cases, medical or surgical treatment aimed at
lowering the intracranial and/or optic nerve sheath pressure
results in progressive involution of peripapillary CNVM
(20–23). For persistent or symptomatic CNVM, intravitreal
anti–vascular endothelial growth factor (anti-VEGF) injec-
tion is the treatment of choice (4–7). We describe the
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management of 10 patients (13 eyes) who developed peri-
papillary CNVM in association with IIH.
METHODS
Research conducted was in compliance with the Health
Insurance Portability and Accountability Act and Declara-
tion of Helsinki, while abiding to all regional, national, and
international laws of the institutions involved in this study.
Every effort was made by the investigators to protect the
rights of the patients. In addition, this study followed the
tenets of the ethics committee of each contributing center
and was approved by the institutional review board of the
University of Michigan.
Patients evaluated between January 1, 2006, and
December 31, 2016, were reviewed and selected from the
following institutions: University of Michigan, W.K.
Kellogg Eye Center, Ann Arbor, Michigan; Department
of Ophthalmology and Visual Neurosciences, University of
Minnesota, Minneapolis, Minnesota; Department of Oph-
thalmology, Duke University Eye Center, Durham, North
Carolina; Department of Ophthalmology, University Hos-
pital Zurich and University of Zurich, Zurich, Switzerland;
Department of Ophthalmology, Washington University, St.
Louis, Missouri; Department of Ophthalmology, Indiana
University School of Medicine, Indianapolis, Indiana; and
Department of Ophthalmology, Hôpital Delafontaine,
Saint-Denis, France. A diagnosis of IIH and a minimum
of 3 months of follow-up after CNVM treatment were
required for study inclusion. Collected data included age,
sex, body mass index (BMI), fundus examination findings,
best-corrected visual acuity (BCVA) at the time of CNVM
diagnosis and at last follow-up, visual field mean deviation
(VFMD), treatment for IIH and CNVM (if any), follow-up
time, MRI and magnetic resonance venography (MRV)
results, lumbar puncture (LP) opening pressures, and status
of papilledema and CNVM at the last follow-up. Patients
with a diagnosis of CNVM before IIH diagnosis were
excluded.
Statistical Package for Social Science v 22.0 software (SPSS,
Chicago, IL) was used to conduct the statistical analyses.
Comparisons between the visits were made using Wilcoxon
signed‐rank. All the reported P values were 2-tailed, and those
less than 0.05 were considered to be statistically significant.
RESULTS
Based on data collected over a 10-year period from one of
the study sites (University of Michigan, W.K. Kellogg Eye
Center), we report a 0.96% prevalence of CNVM in
patients with IIH-associated papilledema and at least 3
months of documented follow-up.
Patient characteristics and treatment results are summarized
in Table 1. A total of 13 eyes of 10 patients (8 women and 2
men) met the inclusion criteria, with a mean age of 35 years
(range 15–54 years). The mean BMI was 35 kg/m2 (range: 19–
48 kg/m2). Brain MRI and MRV were normal except for
dilated optic nerve sheaths in all patients. LP opening pressures
were over 30 cm H2O in all patients. All 13 eyes with CNVM
also had papilledema. Peripapillary subretinal hemorrhage and
subretinal fluid were found in 10 eyes, while 1 eye only had
peripapillary subretinal fluid in association with CNVM (Fig.
1). FA performed in 4 of the 10 patients included in this study
demonstrated hyperfluorescence in the midphase with late leak-
age, indicative of a peripapillary CNVM. The mean elapsed
time between diagnosis of IIH and documentation of a diagno-
sis of CNVM was 41 months. The mean length of follow-up
after CNVM diagnosis was 8 months (range: 3–54 months).
All patients with IIH were treated with oral acetazolamide.
Symptomatic or vision-threatening CNVMs were treated with
intravitreal anti-VEGF injections in 6 eyes. Anti-VEGF injec-
tions were given at the discretion of the treating ophthalmolo-
gist guided by OCT findings. Three eyes received 1
bevacizumab (1.25 mg/0.05 mL) (Avastin; Genentech, Inc,
South San Francisco, CA) injection, 1 eye received 3 bevacizu-
mab injections, 1 eye received 2 bevacizumab and 4 aflibercept
(2.0 mg/0.05 mL) (Eylea; Regeneron, Tarrytown, NY) injec-
tions, and 1 eye received 2 ranibizumab (0.5 mg/0.05 mL)
TABLE 1. Demographics and clinical features of patients with IIH and CNVM
(n = 10 Patients/13 Eyes)
Age 35 (15–54) years
Sex (male/female) 8/2
BMI 35 (19–48) kg/m2
MRI/MRV Normal
LP opening pressure .30 cm H2O
Subretinal hemorrhage and/or fluid 11 eyes
Time for CNVM formation 41 (2–112) months
Follow-up time after CNVM 8 (3–54) months
Treatment for IIH Oral acetazolamide
Data are expressed as the mean (range) of cases.
BMI, body mass index; CNVM, choroidal neovascular membrane; IIH, idiopathic intracranial hypertension; LP, lumbar puncture; n, number;
MRV, magnetic resonance venography.
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FIG. 1. Patient 4. A. There is papilledema with peripapillary subretinal hemorrhage and fluid in the right eye and papilledema
with peripapillary atrophy in the left eye. B. Midphase fluorescein angiogram reveals peripapillary hyperfluorescence sur-
rounded by a ring of hypofluorescence in the right eye. In the left eye, there is peripapillary hyperfluorescence due to CNVM
and an adjacent crescent-shaped hyperfluorescent window defect. C. OCT of the right eye shows intraretinal and subretinal
fluid consistent with an active CNVM. D. OCT of the left eye demonstrates peripapillary thickening with outer retinal atrophy.
Green arrows indicate the direction of the OCT imaging scan. OCT; optical coherence tomography; CNVM, choroidal neo-
vascular membrane.
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(Lucentis; Genentech, Inc) injections. Seven eyes with non–
vision-threatening CNVMs were observed (Table 2). In eyes
managed with observation, the mean interval from time of
diagnosis to time of resolution of CNVM was 248 days (range:
132–435 days). The resolution of CNVM correlated with
improvement of papilledema in these eyes, although persistent
disc edema and elevation were noted at most recent follow-up
in all eyes except one.
Mean BCVA at the time of CNVM diagnosis and at the
last visit was 0.80 ± 0.91 logarithm of the minimum angle of
resolution (logMAR) and 0.60 ± 0.44 logMAR, respectively
(P = 0.62). At the end of the follow-up period, most untreated
and treated eyes either had stable or improved BCVA (Table
2). Mean initial and last BCVA in the observed group was
0.32 ± 0.42 logMAR and 0.37 ± 0.40 logMAR, respectively
(P = 0.63). Mean initial and last BCVA in the treated group
was 1.58 ± 0.98 logMAR and 0.98 ± 0.16 logMAR, respec-
tively (P = 0.37). Mean improvement in VA was 0.05 ± 0.19
logMAR in the observed group and20.60 ± 1.10 logMAR in
the treated group (P = 0.258).
Eight of the 13 eyes included in this investigation
underwent automated (Humphrey) visual field testing at
time of CNVM diagnosis and at most recent follow-up,
which included 3 patients in the treatment group and 5 in
the observation group. The average VFMD for both treated
and untreated eyes at time of CNVM diagnosis and at most
recent follow-up were 28.59 ± 5.60 dB and 25.91 ±
5.45 dB, respectively (P = 0.19). Mean initial and last
VFMD in the observed group was 213.38 ± 7.08 dB
and 28.43 ± 6.07 dB, respectively (P = 0.50). Mean initial
and last BCVA in the treated group was 1.58 ± 0.98 log-
MAR and 0.98 ± 0.16 logMAR, respectively (P = 0.37).
Mean change in BCVA was 01.82 ± 4.20 logMAR in the
observed group and 2.68 ± 2.37 logMAR (P = 0.54) in the
treatment group.
All CNVMs regressed with residual peripapillary sub-
retinal fibrosis either after treatment (Fig. 2) or observation
(Fig. 3). Papilledema resolved completely in only 1 eye,
while the other 12 eyes had improved but persistent disc
edema and elevation at last follow-up.
DISCUSSION
In our multicenter retrospective chart review of patients
who developed peripapillary CNVM secondary to IIH, 10
patients (13 eyes) from 7 different institutions were
included, spanning a 10-year period from the beginning
of the anti-VEGF era in 2006. All patients with IIH were
treated with acetazolamide. Six eyes were treated with
intravitreal anti-VEGF injections, including bevacizumab,
ranibizumab, and aflibercept. The remaining 7 eyes were
managed with close follow-up. Regression of peripapillary
CNVM was documented in all eyes.
Peripapillary CNVM is an infrequent complication of
chronic papilledema and can cause significant vision loss in
patients with IIH. Data on this rare disorder are limited to
few case reports and small case series (8–14). The diagnosis
of CNVM is based on a combination of clinical examina-
tion findings and features observed on OCT and FA. There
is deep peripapillary hemorrhage associated with subretinal
fluid detected on OCT. Although fluid around the disc is
common in patients with IIH, the presence of a grayish‐
white opacity within this area of edema indicates the pres-
ence of a CNVM. On FA, there is hyperfluorescence in the
area of leakage from the CNVM and hypofluorescence in
the area where subretinal hemorrhage is present.















1 F 32 Left FA 20/20 20/60 Bevacizumab · 3 56 Resolved Improved
2 F 26 Right OCT 20/500 20/200 Ranibizumab · 2 8 Resolved Improved
3 M 21 Right FA + OCT 20/30 20/40 Observation 6 Resolved Improved
4 F 51 Right Fundus photography 20/20 20/20 Observation 8 Resolved Improved
Left Fundus photography 20/25 20/25 Observation 8 Resolved Improved
5 F 15 Right OCT 20/40 20/40 Observation 5 Resolved Resolved
6 F 54 Right FA + OCT CF 20/250 Bevacizumab · 1 21 Resolved Improved
7 F 45 Right OCT 20/50 20/40 Observation 8 Resolved Improved
Left OCT Hand
motion
20/100 Bevacizumab · 2,
aflibercept · 4
8 Resolved Improved
8 F 23 Right Fundus photography 20/250 20/250 Bevacizumab · 1 18 Resolved Improved
9 M 48 Left OCT 20/50 20/200 Bevacizumab · 1 3 Resolved Improved
10 F 30 Right FA 20/40 20/32 Observation 14 Resolved Persistent
Left FA 20/400 20/400 Observation 14 Resolved Persistent
CNVM, choroidal neovascular membrane; F, female; FA, fluorescein angiography; IIH, idiopathic intracranial hypertension; M, male; OCT,
optical coherence tomography; Pt, patient; VA, visual acuity.
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Wendel et al (4) reported the largest series of peripapillary
CNVM in patients with IIH-associated papilledema, before the
development of VEGF inhibitors. The authors retrospectively
reviewed 1,140 patients with IIH and identified 6 cases with
peripapillary CNVM, for a prevalence of 0.53%. There were 5
women and 1 man with a mean age of 46.3 years. All patients
had unilateral peripapillary CNVM and were treated with acet-
azolamide or furosemide to lower the intracranial pressure. They
elected observation for 3 patients while 2 were treated with
argon laser photocoagulation and 1 with photodynamic therapy.
At the endpoint of their study, 3 of 6 CNVMs had regressed, 2
were smaller and inactive, and 1 was smaller but with a limited
area of presumed activity. No recurrence of CNVM was noted.
In our study, we elected observation in 7 eyes, and
intravitreal anti-VEGF injections were administered in 6
eyes. The decision to treat was based on the identification of
a CNVM with persistent subretinal fluid threatening the
fovea, expanding retinal exudation, increasing deep peri-
papillary hemorrhage, or a decline in VA out of proportion
with the amount of optic disc edema. All but one eye in our
study showed either stable or improved vision at the end of
follow-up, and all CNVMs completely regressed.
FIG. 2. Patient 2. A. The right fundus shows papilledema with peripapillary subretinal hemorrhage and intraretinal and
subretinal fluid due to CNVM. B. Pretreatment OCT shows subretinal fluid extending into the macula. C. OCT shows resolution
of subretinal fluid after treatment with 2 intravitreal ranibizumab injections. Green arrows indicate the direction of the OCT
imaging scan. CNVM, choroidal neovascular membrane; OCT, optical coherence tomography.
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The causal relationship between developing a peripapillary
CNVM and papilledema is controversial. Kaeser and Borruat
(15) reported a patient with bilateral papilledema and unilat-
eral peripapillary CNVM with spontaneous involution of the
membrane along with improvement of the patient’s vision
from 20/200 to 20/30 after treatment of IIH with acetazol-
amide for 1 year. However, Sathornsumetee et al (2)
described a patient with IIH whose peripapillary CNVM
did not regress and VA that did not improve after optic nerve
sheath fenestration, despite dramatic improvement in the
degree of papilledema. In our study, all 13 peripapillary
CNVMs regressed with concurrent improvement in papille-
dema. It is unclear whether our findings are related to med-
ical therapy of IIH, treatment of the CNVM, or simply due
to the natural course of the CNVM.
The pathogenesis of peripapillary CNVM in patients with
papilledema due to IIH is unclear, but it seems to be different
from CNVMs that occur in other posterior segment diseases
such as exudative age-related macular degeneration (16–19). In
macular degeneration, retinal pigment epithelium dysfunction
and Bruch membrane breaks occur as a result of retinal drusen
deposition and inflammation, which subsequently promotes
hypoxia and angiogenesis (19,20). Peripapillary CNVM in
IIH might result from a pressure deformity of the Bruch
membrane at the level of the optic nerve head (16). This
combined with persistent hypoxic environment created by
axonal swelling may initiate the angiogenesis cascade, leading
to the neovascular membrane formation (21,22).
Management options for peripapillary CNVM in patients
with IIH include observation, subretinal surgery, laser photo-
coagulation, photodynamic therapy, or intravitreal injection of
anti-VEGF agents (3,6,16,23,24). Although therapeutic deci-
sions must be made on a case-by-case basis, the use of anti-
VEGF agents currently is the method of choice (1,7,23,24).
Our study has several limitations, including the method
of diagnosis of CNVM. In each case, the diagnosis of
CNVM was made clinically with supporting features
observed on retinal imaging. Not all patients underwent
both OCT and FA. Other limitations of our report include
retrospective design and small sample size.
In conclusion, peripapillary CNVM in association with
papilledema due to IIH may regress spontaneously with no
vision loss with adequate medical treatment of IIH. In
vision-threatening cases, intravitreal injection of bevacizu-
mab, ranibizumab, or aflibercept may be an effective
treatment option to preserve visual function.
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